Healthcare
Live Price
Offline$3.35
+6.01% today
1Y Change
+0.76%
Window
Jun 23, 2025 → Jun 9, 2026
Coverage: 242 bars · Jun 23, 2025 → Jun 9, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Rocket Pharmaceuticals, Inc. (RCKT) is a Healthcare stock with a market cap of $390.00M and listed on NASDAQ. The stock last traded around $3.35 and up 0.8% across the available one-year price window (Jun 23, 2025 → Jun 9, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +26.4%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +26.4%, free cash flow +11.7% with operating margin 0.0% and ROIC -76.4%. Stock Foundry combines RCKT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RCKT
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RCKT Max Drawdown
-50.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RCKT and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$169.1M
+23.8% YoY
Free Cash Flow
-$128.9M
+31.0% YoY
Revenue Growth
+0.0%
EPS Growth
+26.4%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -11M | 0 | 0 | 0 | 0 |
| Operating Income | -229M | -273M | -260M | -224M | -167M |
| EBITDA | -210M | -247M | -237M | -214M | -158M |
| Net Income | -223M | -259M | -246M | -222M | -169M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 78M | 164M | 56M | 141M | 233M |
| Total Assets | 330M | 528M | 566M | 552M | 497M |
| Total Liabilities | 53M | 64M | 74M | 62M | 42M |
| Shareholder Equity | 277M | 463M | 493M | 490M | 455M |
| Total Debt | 25M | 25M | 25M | 23M | 23M |
| Net Debt | -53M | -138M | -31M | -118M | -210M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
121M
+32.0% YoY
Capital Expenditures
8M
+10.5% YoY
Free Cash Flow
129M
+31.0% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-65.8%
Debt / Equity
0.09x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.